Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TRD205 in Healthy Adults
NCT07123428Phase 1Completed
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Nov 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TRD205 in neuropathic pain (6 arms), sponsored by Beijing Tide Pharmaceutical Co., Ltd. Primary endpoint: Treatment-Related Adverse Events at 10 days. Started Jan 2024; status: completed.
02
Drugs
TRD205
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT07123428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123428.